title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Thursday,20220428T193101,https://www.benzinga.com/markets/options/22/04/26872967/52-weeks-high-and-low-article,IKNA,0.00644,Neutral,-0.000688
Stocks That Hit 52-Week Lows On Wednesday,20220427T184104,https://www.benzinga.com/markets/options/22/04/26844275/52-weeks-high-and-low-article,IKNA,0.006956,Neutral,0.01199
"Earnings Scheduled For March 17, 2022",20220317T085447,https://www.benzinga.com/news/earnings/22/03/26177874/earnings-scheduled-for-march-17-2022,IKNA,0.028432,Neutral,0.000317
77 Biggest Movers From Yesterday,20220601T090222,https://www.benzinga.com/news/22/06/27492435/77-biggest-movers-from-yesterday,IKNA,0.085721,Neutral,-0.007183
64 Biggest Movers From Yesterday,20220318T092329,https://www.benzinga.com/news/22/03/26196687/64-biggest-movers-from-yesterday,IKNA,0.059533,Neutral,0.003809
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",20230803T210100,https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,IKNA,0.02074,Neutral,-0.002722
